Clinical Trials Logo

Deep Vein Thrombosis clinical trials

View clinical trials related to Deep Vein Thrombosis.

Filter by:

NCT ID: NCT04917328 Recruiting - Clinical trials for Deep Vein Thrombosis

Compression Ultrasonography in Non-high Probability of Deep Vein Thrombosis

EPREVUP
Start date: February 21, 2022
Phase: N/A
Study type: Interventional

Compression ultrasound is commonly used in emergency department. Accuracy to rule out deep vein thrombosis is excellent but lower then Ddimer assessment which is actually gold standard. With progress in formation of emergency physicians (EP), quality of material used, the investigators hypothesize that compression ultrasound can rule out deep vein thrombosis in case of non high probability, as standard care and DDimer assay.

NCT ID: NCT04913688 Recruiting - Clinical trials for Deep Vein Thrombosis

The Learning Curve of Emergency Physicians Performed Lower-extremity Ultrasonography in the Diagnosis of DVT

Start date: May 1, 2021
Phase:
Study type: Observational

If deep vein thrombosis (DVT) is suspected among patients who have symptoms such as pain or swelling of the lower extremities, duplex ultrasound of the lower limb is the first-line imaging modality to diagnose DVT. However, duplex ultrasound is time consuming, requires patient transport to a diagnostic imaging facility. In recent years, abbereviated bedside ultrasound technique has been accepted by emergency physician to diagnose the presence of DVT. Several studies have proven that the accuracy of this abbreviated bedsude ultrasound for assessing the presence of deep vein thrombosis is not inferior to experts, but how much ultrasound experience is required to obtain the accuracy that does not inferior to experts has yet to be studied. The aim of this study is to identify how much learning by emergency physicians is needed to obtain the accuracy of the lower extremity ultrasound examination comparable to that of experts.

NCT ID: NCT04741464 Recruiting - Clinical trials for Deep Vein Thrombosis

Effect of Tinzaparin on Inflammatory Biomarkers During the Acute Phase of Deep Vein Thrombosis

Aticks Live
Start date: February 2, 2021
Phase: N/A
Study type: Interventional

Anticoagulants influence either coagulation, inflammation and inflammatory processes in deep vein thrombosis (DVT). Acute DVT cause an inflammatory response that may persist for a long period of time. There is a need to describe patterns of change in serum biomarker levels after acute DVT, and explore the association between trajectory biological patterns and clinical evolution in the era of various anticoagulants in the acute phase of treatment in order to be able to further avoid recurrence and late sequelae. It appears that direct oral anticoagulants and heparin alter inflammatory markers in different ways. It is therefore important to study the evolution of markers according to the different treatments used and secondarily to compare them with each other. Tinzaparin is used in the long term in patients with DVT, it is necessary to measure the evolution of inflammatory markers and then in another study to compare with the other molecules.

NCT ID: NCT04694248 Recruiting - Clinical trials for Deep Vein Thrombosis

Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting

Start date: November 3, 2021
Phase: N/A
Study type: Interventional

To evaluate the efficacy and safety of combination of anticoagulant and antiplatelet therapy on the patency of iliac vein at 12-month post stenting in patients with acute proximal DVT and ipsilateral iliac vein stenosis who received percutaneous mechanic thrombectomy and iliac vein stenting.

NCT ID: NCT04674202 Recruiting - Atrial Fibrillation Clinical Trials

Pilot Study: Comparison of Patients' Knowledge of Direct Oral Anticoagulants in Post-hospitalization Between 2 Cardiology Departments Offering or Not a Pharmaceutical Interview During Hospitalization

EDUC-AOD
Start date: January 18, 2021
Phase:
Study type: Observational

Direct oral anticoagulants (Rivaroxaban, Apixaban and Dabigatran) are an alternative to anti-vitamin K drugs and low molecular weight heparins in many cardiovascular diseases. This new class of anticoagulants represents a particular and very promising advance: they are administered orally, their mechanism of action is rapid and direct on coagulation and their predictable pharmacological action allows for administration at fixed doses. In contrast to anti-vitamin K, there is no need for routine biological monitoring. However, their therapeutic range is narrow and there is no routine biological monitoring. Rigorous compliance is therefore necessary. In addition, there are no official validated recommendations either for the measurement of anticoagulant activity in certain emergency situations, or for the management of severe bleeding (except recently for Pradaxa®). Their correct use requires the training and involvement of health professionals as well as information and support for patients. Pharmaceutical interviews are one of the main ways in which pharmacists can ensure this security through personalized and optimal patient care. The purpose of these interviews is to: - Reinforce the pharmacist's advisory, educational and preventive roles with patients; - To enhance the pharmacist's expertise in the area of medication; - To evaluate the patient's knowledge of his or her treatment; - To assess the patient's knowledge of his or her treatment; To seek the patient's therapeutic adherence and help him or her to take ownership of his or her treatment; - To evaluate, in the long term, the patient's appropriation of his or her treatment. In this way, they enable involvement with patients while providing a link between healthcare professionals, which is essential for optimal patient care. In recent years, numerous studies have been conducted on pharmaceutical interviews in the United Kingdom and the Netherlands. On the other hand, few studies have been conducted in France to evaluate the clinical impact of pharmaceutical interviewing in medical services. The aim of this study is to compare patients' knowledge of direct oral anticoagulants between 2 cardiology departments offering or not a pharmaceutical interview.

NCT ID: NCT04462003 Recruiting - Clinical trials for Deep Vein Thrombosis

Efficacy of Apixaban in Malignancy With Deep Venous Thrombosis

DVT
Start date: July 3, 2019
Phase: Phase 3
Study type: Interventional

The aim of study was to evaluate the efficacy and safety of Apixaban in patients with acute deep venous thrombosis and active malignancy compared with weight adjusted subcutaneous (LMWH). It was hypothesised that Apixaban could be as effective as rivaroxiban and edoxaban in treatment of patients with acute DVT and active malignancy with a lower risk of bleeding especially in those with GIT cancer.

NCT ID: NCT04335162 Recruiting - Clinical trials for Myocardial Infarction

Cardiovascular Complications and COVID-19 (CovCardioVasc-Study)

CovCardioVasc
Start date: February 28, 2020
Phase:
Study type: Observational

Patients with COVID-19 in the Intensive Care Unit (ICU) or hospitalized with severe form have a poor prognosis (almost 30% rate of death). They present often a high cardiovascular risk profile (almost 30% of hypertension and 19% of diabetes). Troponin has been described to be elevated in a high proportion of patients (one fifth of all patients and 50% of non-survivors) suggesting the possibility of cardiomyopathies. High levels of DDimers (81% of non survivors) and fibrin degradation products are also associated with increased risk of mortality suggesting also the possibility of venous thromboembolism. Therefore, screening for cardiomyopathies and venous thromboembolism could represent an important challenge for patients with COVID-19 management.

NCT ID: NCT04252651 Recruiting - Clinical trials for Deep Vein Thrombosis

Association of Cytokines With the Development of Complications in Burn and Toxic Epidermal Necrolysis (TENS) Patients

Start date: October 2, 2019
Phase:
Study type: Observational

This study will involve blood draws to test for specific cytokines. The study goal is to gain a better understanding of the role of inflammatory response in the development of specific complications in burn and TENS patients.

NCT ID: NCT04169269 Recruiting - Clinical trials for Venous Thromboembolism

Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban

Start date: January 13, 2020
Phase: Phase 4
Study type: Interventional

The objective of this study is to compare oral rivaroxaban with injectable enoxaparin in orthopaedic trauma patients to determine if orally administered rivaroxaban once daily carries greater compliance and overall satisfaction than enoxaparin self-administered by subcutaneous injection once daily.

NCT ID: NCT04022915 Recruiting - Pulmonary Embolism Clinical Trials

PET Fibrin Imaging of DVT and PE

Start date: May 13, 2019
Phase: Phase 1
Study type: Interventional

This study aims to investigate a novel positron emission tomography(PET)-probe for imaging of fresh intravascular blood clots in pulmonary embolism (PE) and deep venous thrombosis (DVT).